Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence

BACKGROUND: MODIFY I/II were global trials of the efficacy and safety of bezlotoxumab (BEZ), a monoclonal antibody (mAb) against C. difficile toxin B, alone and with actoxumab (ACT), a mAb against C. difficile toxin A. BEZ was superior to placebo (PBO) at preventing recurrent CDI (rCDI) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Ciaran P, Poxton, Ian R, Shen, Judong, Railkar, Radha, Guris, Dalya, Dorr, Mary Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631063/
http://dx.doi.org/10.1093/ofid/ofx163.965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631063/
http://dx.doi.org/10.1093/ofid/ofx163.965

Ejemplares similares